September 8, 2017 / 5:51 AM / in 2 months

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

Sept 8 (Reuters) - NICOX SA:

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​

* H1 OPERATING LOSS EUR ‍​11.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO

* ‍INVESTIGATIONAL NEW DRUG (IND) SUBMISSIONS FOR NCX 470 FOR IOP LOWERING AND NCX 4251 FOR BLEPHARITIS PLANNED FOR H1​

* H1 NET LOSS OF THE YEAR EUR 12.2‍​ MILLION VERSUS LOSS OF EUR 24.2 MILLION YEAR AGO

* ‍BAUSCH + LOMB RESPONDED TO VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% COMPLETE RESPONSE LETTER (CRL) RECEIVED FROM FDA​

* REPORTS H1 NO REVENUE VERSUS EUR 9,000 YEAR AGO

* NET LOSS FROM CONTINUING OPERATIONS EUR 12.2 MILLION AS OF JUNE 30, 2017, VERSUS NET LOSS OF EUR 12.9 YEAR AGO

* ‍CASH, CASH EQUIVALENTS OF EUR 20.4 MILLION AS OF JUNE 30, 2017, COMPARED TO EUR 28.9 MILLION ON DECEMBER 31, 2016​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below